Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Elizabeth I. Buchbinder"'
Autor:
Michael Dougan, Elizabeth I. Buchbinder, Meredith Davis, Anita Giobbie-Hurder, William Martin-Doyle, Patrick A. Ott, Osama E. Rahma, Maria Gargano, F. Stephen Hodi, Shilpa Grover, Rawad Elias, Rizwan Haq, Taha Qazi, Kruti Vora, Steven M. Blum, Jeffrey J. Ishizuka, Kevin Tyan, Ryan J. Sullivan, Michael Manos, Lauren Eastman, Alex B. Ruan
Publikováno v:
Cancer
Background There is a lack of predictive markers informing on the risk of colitis in patients treated with immune checkpoint inhibitors (ICIs). The aim of this study was to identify potential factors associated with development of ICI colitis. Method
Autor:
F. Stephen Hodi, Jason J. Luke, Elizabeth I. Buchbinder, Paul Leger, Richard W. Joseph, Fei Ye, Daniel Y. Wang, Rizwan Haq, Jeffrey A. Sosman, Zeynep Eroglu, Alpaslan Özgün, Shilin Zhao, Douglas B. Johnson, Patrick A. Ott
Anti–PD-1 therapy has improved clinical outcomes in advanced melanoma, but most patients experience intrinsic resistance. Responding patients can develop acquired resistance to anti–PD-1. We retrospectively reviewed 488 patients treated with anti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31445cdc384b37272d7330b860af374c
https://europepmc.org/articles/PMC5502536/
https://europepmc.org/articles/PMC5502536/
Autor:
Ryan M. Merritt, David F. McDermott, Eirini Pectasides, Jeffrey A. Sosman, Emily Feld, Elizabeth I. Buchbinder, Fei Ye, Shilin Zhao, Douglas B. Johnson, Ryan J. Sullivan, Donald P. Lawrence, Romany A. N. Johnpulle, Igor Puzanov
Publikováno v:
J Immunother
Novel agents targeting immune checkpoint molecules or mutated BRAF are active therapeutic options for patients with BRAF(V600)-mutant melanoma. However, the most effective first-line treatment and the optimal sequencing of these agents have not been
Autor:
Jeffrey S. Weber, Theodore F. Logan, Elmer Berghorn, Jeffrey A. Sosman, Suresh G. Nair Md, Donald P. Lawrence, Leslie A. Fecher, Christine Horak, George Kong, Lynn M. Schuchter, Craig L. Slingluff, Geoff Gibney, Joel Jiang, F. Stephen Hodi, Elizabeth I. Buchbinder, Mary Ruisi, Ryan J. Sullivan
Publikováno v:
The Lancet. Oncology. 17(7)
Summary Background Concurrent administration of the immune checkpoint inhibitors nivolumab and ipilimumab has shown greater efficacy than either agent alone in patients with advanced melanoma, albeit with more high-grade adverse events. We assessed w
Publikováno v:
Nature reviews. Clinical oncology. 13(2)
The relationship between cancer and the immune system is complex and provides unique therapeutic opportunities. Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a regulatory molecule that suppresses T cell effector function following initial activation b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74cdb66678a5aed8cc5df3d17b7fb4a6
https://europepmc.org/articles/PMC4588295/
https://europepmc.org/articles/PMC4588295/
Publikováno v:
Clinical therapeutics. 37(4)
Purpose Melanoma is an aggressive malignancy that has a complex relationship with the host immune system. Immunotherapies have long been a mainstay of melanoma therapy, and advanced therapies continue to be effective in treating this disease. Immune
Autor:
Michael A. Davies, Richard W. Joseph, John A. Jakob, Alexander S. Parker, Ryan J. Sullivan, Patrick Hwu, Elizabeth I. Buchbinder, Ruchi G. Sharma, Roland L. Bassett, Jeanette E. Eckel-Passow, Michael B. Atkins, Ping Liu
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997). 35(9)
Ipilimumab improves overall survival (OS) in patients with metastatic melanoma including those previously treated with high-dose interleukin-2 (HD IL-2). The primary objective of this study was to determine if clinical response or progression-free su
Autor:
Carolin Bender, Alexander Guminski, Howard L. Kaufman, Jeffrey A. Sosman, Jenny H. Lee, Janice M. Mehnert, Joseph I. Clark, Donald P. Lawrence, Jessica C. Hassel, Tejaswi V. Mudigonda, Matteo S. Carlino, Fei Ye, Kristen Spencer, Patrick A. Ott, Ryan J. Sullivan, Nikhil I. Khushalani, Elizabeth I. Buchbinder, Douglas B. Johnson, Georgina V. Long, Igor Puzanov, Alexander M. Menzies
Publikováno v:
JAMA Oncology. 2:234
Importance Ipilimumab and other immune therapies are effective treatment options for patients with advanced melanoma but cause frequent immune-related toxic effects. Autoimmune diseases are common, and the safety and efficacy of ipilimumab therapy in